NCT00002107已完成1 期
A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable subcutaneous regimen that will replicate the immunologic improvement demonstrated in the outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies. To evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient population.
详细描述
Patients will receive subcutaneous Proleukin, and the MTD will be determined.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected PatientsHIV InfectionNCT00001357National Institute of Allergy and Infectious Diseases (NIAID)80
已完成
1 期
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host DiseaseGraft Versus Host DiseaseNCT00529035Dana-Farber Cancer Institute29
已完成
1 期
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune SystemsHIV InfectionsNCT00006066National Institute of Allergy and Infectious Diseases (NIAID)92
已完成
2 期
A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3HIV InfectionsNCT00000889National Institute of Allergy and Infectious Diseases (NIAID)72
已完成
1 期
Low Dose IL-2 for Ulcerative ColitisUlcerative ColitisNCT02200445Scott B. Snapper, MD PHD26